Corboz M R, Rivelli M A, Mingo G G, McLeod R L, Varty L, Jia Y, Hey J A
Pulmonary and Peripheral Neurobiology, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Pulm Pharmacol Ther. 2008;21(3):449-54. doi: 10.1016/j.pupt.2007.06.007. Epub 2007 Jul 17.
The vascular bed in nasal mucosa of different species, including human, is highly vascularized and an extensive sinusoidal network of large capacitance vessels is present deep within the submucosa. When this network of venous sinusoids is engorged with blood, the swollen mucosa reduces the size of the airway lumen and congestion ensues. Nasal vasculature tone is strongly influenced by the sympathetic nervous system and the only drugs approved specifically to relieve vascular nasal obstruction are alpha-adrenoceptor sympathomimetic agents. Due to their vasoconstrictor action, the sympathomimetic decongestants oppose vasodilation, reducing nasal airway resistance and thus facilitating nose breathing. However, standard decongestants that are non-selective alpha-adrenoceptor agonists are associated with the potential for side-effect liabilities including hypertension, stroke, insomnia and nervousness. We propose than a selective alpha 2-adrenoceptor agonist, by acting preferentially on nasal venous capacitance vessels, will elicit decongestion with a reduced side-effect liability. In the present study, we evaluated the effects of the selective alpha 2-adrenoceptor agonist BHT-920 in a real-time tissue contractility assay using isolated pig nasal explants and in an in vivo cat model of congestion. The vasoconstrictor and decongestant effects of BHT-920 were compared to the non-selective alpha-adrenoceptor agonist epinephrine and the standard decongestant oxymetazoline. Our results showed that the alpha 2-adrenoceptor agonist BHT-920 preferentially contracts venous sinusoids confirming previous observations [Corboz MR, Varty LM, Rivelli MA, Mutter JC, Mingo G, McLeod R, et al. Effects of an alpha 2-adrenoceptor agonist in nasal mucosa. Arch Physiol Biochem 2003;11: 335-6, Corboz MR, Rivelli MA, Varty LM, Mutter J, Cartwright M, Rizzo CA, et al. Pharmacological characterization of postjunctional alpha-adrenoceptor in human nasal mucosa. Am J Rhinol 2005;19: 495-502] and displays decongestion without affecting blood pressure. Therefore, an alpha 2-adrenoceptor agonist, by causing constriction in the capacitance vessels of nasal mucosa, can produce nasal decongestion without the effects on blood pressure observed with the standard selective alpha 1-adrenoceptor and non-selective alpha-adrenoceptor sympathomimetic decongestants.
包括人类在内的不同物种的鼻黏膜血管床血管高度丰富,黏膜下层深处存在广泛的大容积血管窦状网络。当这个静脉窦状网络充血时,肿胀的黏膜会减小气道管腔的大小,继而出现充血。鼻血管张力受交感神经系统的强烈影响,专门批准用于缓解血管性鼻阻塞的唯一药物是α-肾上腺素能受体拟交感神经药。由于其血管收缩作用,拟交感神经减充血剂可对抗血管舒张,降低鼻气道阻力,从而促进鼻呼吸。然而,非选择性α-肾上腺素能受体激动剂的标准减充血剂存在副作用风险,包括高血压、中风、失眠和紧张。我们提出,一种选择性α2-肾上腺素能受体激动剂通过优先作用于鼻静脉容量血管,将引起减充血且副作用风险降低。在本研究中,我们使用分离的猪鼻外植体在实时组织收缩性测定以及在体内充血猫模型中评估了选择性α2-肾上腺素能受体激动剂BHT-920的作用。将BHT-920的血管收缩和减充血作用与非选择性α-肾上腺素能受体激动剂肾上腺素和标准减充血剂羟甲唑啉进行了比较。我们的结果表明,α2-肾上腺素能受体激动剂BHT-920优先使静脉窦收缩,证实了先前的观察结果[Corboz MR, Varty LM, Rivelli MA, Mutter JC, Mingo G, McLeod R等。α2-肾上腺素能受体激动剂对鼻黏膜的作用。《生理生化杂志》2003年;11: 335 - 6,Corboz MR, Rivelli MA, Varty LM, Mutter J, Cartwright M, Rizzo CA等。人鼻黏膜节后α-肾上腺素能受体的药理学特征。《美国鼻科学杂志》2005年;19: 495 - 502],并显示出减充血作用而不影响血压。因此,一种α2-肾上腺素能受体激动剂通过引起鼻黏膜容量血管收缩,可产生鼻减充血作用,而不会出现标准选择性α1-肾上腺素能受体和非选择性α-肾上腺素能受体拟交感神经减充血剂所观察到的对血压的影响。